Are the innovations shaping the future of preclinical research in India?

Preclinical research in India is evolving rapidly due to advancements in technology, regulatory changes, and increasing investment in biotech and pharma. Key innovations shaping the future of preclinical research in India include:

1. AI & Machine Learning in Drug Discovery

• AI-driven computational models help in predicting drug efficacy and toxicity, reducing the need for excessive animal testing.
• Machine learning is used for analyzing large datasets from genomics, proteomics, and metabolomics.

2. Organoids & 3D Cell Cultures

• Miniature, lab-grown human organ models (organoids) are replacing traditional 2D cell cultures and animal models.
• They provide better physiological relevance and enable personalized medicine research.

3. CRISPR & Gene Editing Technologies

• CRISPR is being used to create genetically modified models for studying disease mechanisms and testing new therapies.
• This accelerates drug discovery and improves model accuracy.

4. In Silico & Virtual Screening Methods

• Computer-based simulations and AI-driven virtual screening reduce time and cost in identifying potential drug candidates.
• These methods complement traditional in vitro and in vivo studies.

5. Regulatory Improvements & GLP-certified Labs

• India’s regulatory agencies, like CDSCO and ICMR, are modernizing guidelines for preclinical studies.
• Growth of Good Laboratory Practice (GLP)-certified facilities ensures data credibility for global regulatory approvals.

6. Microfluidics & Lab-on-a-Chip Technology

• These miniaturized systems mimic human physiological conditions, reducing reliance on animal testing.
• They enable high-throughput screening of drug responses.

7. Non-Animal Testing Models (Alternatives to Animal Testing)

• India is increasing its focus on ethical research alternatives like microphysiological systems and AI-driven toxicity prediction.
• The use of zebrafish models is also gaining traction as a bridge between in vitro and in vivo studies.

8. Collaborations & Public-Private Partnerships

• Increased collaboration between Indian pharma, biotech startups, academia, and global companies enhances innovation.
• Government initiatives like Make in India and Startup India support biotech research infrastructure.

9. AI-driven Toxicology & Predictive Pharmacology

• AI tools help assess drug toxicity and side effects early in preclinical trials.
• This reduces late-stage failures and enhances drug safety profiling.

10. Bioprinting & Tissue Engineering

• Advances in bioprinting allow researchers to develop complex human tissue models for drug testing.
• This bridges the gap between in vitro studies and human trials.

With these innovations, India’s preclinical research landscape is becoming more efficient, ethical, and globally competitive.

​Moreover India’s preclinical research landscape is being transformed by a host of innovative companies and collaborations. Here are some notable entities driving advancements in this field:​

1. Novo Nordisk’s AI Collaborations

The Danish pharmaceutical company Novo Nordisk is significantly expanding its operations in India. It has partnered with 10 Indian AI startups to enhance various aspects of drug development, including document summarization, insight extraction, and quality checks. These AI tools have notably reduced document processing times from 40 hours to just 40 minutes, demonstrating the efficiency gains achievable through such collaborations. Novo Nordisk plans to double its global process leaders in India over the next three to four years and increase its overall headcount by 16% to 5,000 in the coming year. ​

2. Sanofi’s Investment in AI and Digital Technologies

French pharmaceutical giant Sanofi has announced plans to invest $437 million in its India center. This investment underscores Sanofi’s commitment to leveraging AI and digital technologies to enhance drug development processes, reflecting a broader industry trend toward integrating advanced technologies in preclinical research. ​

3. Bristol Myers Squibb’s Hyderabad Facility Expansion

Bristol Myers Squibb is expanding its Hyderabad facility, aiming to make it the company’s largest unit outside the U.S. by 2025. This expansion focuses on enhancing drug development through the use of AI and digital technologies, highlighting the growing importance of India’s role in global pharmaceutical research and development.

4. Biocon Limited

Biocon, one of India’s leading biopharmaceutical companies, is actively involved in preclinical research and development. The company focuses on innovative therapies in areas such as oncology, immunology, and diabetes, utilizing advanced technologies to drive its research initiatives.​

5. Syngene International

Syngene, a subsidiary of Biocon, offers integrated research and development services. It provides preclinical research solutions, including drug discovery and development services, to global pharmaceutical companies, leveraging state-of-the-art facilities and technologies.​

6. Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in India that engages in preclinical research across various therapeutic areas. The company invests in innovative technologies and collaborations to advance its drug discovery and development efforts.​

7. Zydus Cadila

Zydus Cadila is an Indian pharmaceutical company involved in preclinical research, focusing on developing novel therapies. The company employs advanced research methodologies and technologies to accelerate drug discovery and development.​

These companies and collaborations exemplify the dynamic and innovative environment of preclinical research in India, driven by technological advancements and strategic partnerships.

Reference: www.reuters.com